ANDA 200384, held by Naari Pte. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 200384 (Norgestimate And Ethinyl Estradiol), held by Naari Pte, was first approved by FDA on Apr 7, 2015, with 3 approved supplements and 0 published complete response letters.
Norgestimate and ethinyl estradiol tablets USP are estrogen/progestin COCs, indicated for use by women to prevent pregnancy. 1.1 Oral Contraceptive Norgestimate and ethinyl estradiol tablets USP are indicated for use by females of reproductive potential to prevent pregnancy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 31, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 31, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 7, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters